Document is current
Any future updates will be listed below
-
Authors
Li, Xue
Huang, Yingying
Liu, Chenyao
Chang, Xindan
Cui, Zaifeng
Yang, Qiulin
Drobe, Björn
Bullimore, Mark A.
Chen, Hao
Bao, Jinhua https://orcid.org/0000-0002-2103-8345
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2100047262 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study
https://doi.org/10.1186/s40662-025-00427-3
-
Funding
Funding for this research was provided by:
Science Fund for Distinguished Young Scholars of Zhejiang Province (LQ23H120003)
Medical and Health Science and Technology Project of the Zhejiang Provincial Health Commission (2022PY072)
Eye Hospital， Wenzhou Medical University (HXKT-202404)
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 13 February 2025
First Online: 5 March 2025
Declarations
:
: The study received approval from the Ethics Committee of the Eye Hospital, Wenzhou Medical University (2021-087-K-74) and was registered with the Chinese Clinical Trial Registry (ChiCTR2100047262). All the procedures were conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent and assent were obtained from the participants and their parents or guardians before participation.
: Not applicable.
: Björn Drobe is an employee of EssilorLuxottica, which supplied the study devices and is inventor of patents related to the study device. Mark Bullimore is a consultant for Alcon Research, CooperVision, Dopavision, EssilorLuxottica, Euclid Vision, Eyenovia, Genentech, Johnson & Johnson Vision, Kubota Vision, Novartis, Sydnexis, and Vyluma. The other authors have no proprietary or commercial interest in any materials discussed in this article.
